Non-alcoholic fatty liver disease (NAFLD) has become one of the most prominent forms of
chronic liver disease worldwide, reflecting the epidemic of global obesity. Those with the
progressive variant of NAFLD, non-alcoholic steatohepatitis (NASH), are at significantly
increased risk of multisystem morbidity and mortality. However, there are currently no
approved pharmacologic therapies for NASH. Given the disease burden, there is an
important unmet need for pharmacologic treatment options for this patient population. The …